OBJECTIVE：To provide reference for drug procurement and supply and rational use of lipid-regulating agents. METHODS：The epidemiological investigation was carried out among 159 506 cases from 74 hospitals in Beijing，Chengdu， Guangzhou，Hangzhou，Shanghai and Tianjin in 2013. The utilization of lipid-regulating agents was analyzed statistically in respects of purchase value，DDDs，DDC，actual average daily dose and sort ratio. RESULTS：The prevalence rate of hyperlipidemia was relatively high，accounting for 29.56％ and showing a tendency of regional distribution and young age in all regions. The patients with hypertension，diabetes and coronary heart disease had a higher incidence to suffer from hyperlipidemia. The use of atorvastatin was in the first place，but it also had a higher DDC；while rosuvastatin hasd the advantage over aorvastatin in drug market. Simvastatin had a lower DDC and was more suitable for the patients with low income. The doses of lipid-regulating agents in other regions were lower than DDD except for those in Beijing and Tianjin. CONCLUSIONS：Statins dominate the lipid-regulating agents market. But new lipid-regulating agents and drug combination provide a new choice for clinical treatment.